Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)

NCT00621855 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00621855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00621855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
Not reported
Enrollment
1,878 (actual)
Sites
167

Conditions

As the registry lists them; a condition with its own page is linked.

coronary disease